What do we really know about reference pricing of pharmaceuticals?

Galizzi, Matteo M. ORCID: 0000-0002-7757-5625, Ghislandi, Simone and Miraldo, Marisa (2011) What do we really know about reference pricing of pharmaceuticals? Eurohealth, 17 (1). pp. 17-19. ISSN 1356-1030

Full text not available from this repository.

Abstract

Health policy-makers worldwide have adopted different Reference Pricing (RP) systems for pharmaceuticals. Systems may differ concerning their effects on pharmaceutical prices, firms’ strategies, market structure, public and private expenditure, health outcomes and Research and Development (R&D) investments. We present evidence from a recent systematic review of the effects of RP across different systems. Evidence suggests RP successfully decreases drug prices and expenditures in the short-run. Prices drop more where generics have more market power. There is no evidence of negative health effects associated with patients switching between drugs. More research is needed on the long-term effects of RP and its impact on R&D.

Item Type:	Article
Official URL:	http://www.euro.who.int/en/home
Additional Information:	© 2011 The Authors
Divisions:	Social Policy
Subjects:	R Medicine > RA Public aspects of medicine
Date Deposited:	19 Feb 2015 15:37
Last Modified:	01 Nov 2024 05:22
URI:	http://eprints.lse.ac.uk/id/eprint/61008

Actions (login required)

View Item